RELAX-AHF shows first positive findings in HFpEF patients European Society of Cardiology

<P>Contact: Jacqueline Partarrieu<BR>press@escardio.org<BR>33-492-947-756<BR>European Society of Cardiology <BR>
<P>Lisbon, 26 May 2013: Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented in today's late breaking trial session1 at the Heart Failure Congress 2013. Results were also presented from

Read more ...